Gender, geography and socio-economic status in the diffusion of malignant melanoma risk

Aase, Asbjørn; Bentham, Graham

doi:10.1016/0277-9536(95)00318-5

Cited by 29 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…People with moderate or highly pigmented skin exhibit a low risk of developing melanoma. Among European Caucasians, there are important differences with respect to skin color:1, 26 southern European populations have higher levels of skin pigmentation than northern European populations. Also, northern European populations may have been exposed to more intermittent exposures due to differences in sun behavior and faraway holiday experiences.…”

Section: Discussionmentioning

confidence: 99%

Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia

Vries

Bray²,

Coebergh

et al. 2003

Intl Journal of Cancer

339

255

View full text Add to dashboard Cite

We analyzed time trends in incidence of and mortality from malignant cutaneous melanoma in European populations since 1953. Data were extracted from the EUROCIM database of incidence data from 165 cancer registries. Mortality data were derived from the WHO database. During the 1990s, incidence rates were by far highest in northern and western Europe, whereas mortality was higher in males in eastern and southern Europe. Melanoma rates have been rising steadily, albeit with substantial geographic variation. In northern Europe, a deceleration in these trends occurred recently in persons aged under 70. Joinpoint analyses indicated that changes in these trends took place in the early 1980s. In western Europe, mortality rates have also recently leveled off [estimated annual percentage change (EAPC) from -13.6% (n.s.) to 3.3%], whereas in eastern and southern Europe both incidence and mortality rates are still increasing [incidence EAPCs 2.3-8.9%, mortality EAPCs -1.8% (n.s.) to 7.2%]. Models including the effects of age, period and birth cohort were required to adequately describe the rising incidence trends in most European populations, with a few exceptions. Time trends in mortality were adequately summarized on fitting either an age-cohort model (with the leveling off of rates starting in birth cohorts between 1930 and 1940) or an age-period-cohort model. The most plausible explanations for the deceleration or decline in the incidence and mortality trends in recent years in northern (and to a lesser extent western) Europe are earlier detection and more frequent excision of pigmented lesions and a growing public awareness of the dangers of excessive sunbathing.

show abstract

Section: Discussionmentioning

confidence: 99%

Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia

Vries

Bray²,

Coebergh

et al. 2003

Intl Journal of Cancer

339

255

View full text Add to dashboard Cite

show abstract

“…Significant differences exist between male and female patients in melanoma incidence, presentation of primary tumor, and mortality [1][2][3]. In European countries, incidence rates for melanoma are higher for women compared with men [1,[4][5][6]. In the United States and Australia, the incidence is higher among men [7].…”

Section: Introductionmentioning

confidence: 95%

Sex differences in survival of cutaneous melanoma are age dependent

et al. 2011

View full text Add to dashboard Cite

This study identified sex differences in clinical presentation and survival for primary cutaneous melanoma without clinical evidence of metastasis at diagnosis from 1976 to 2008 in southern Germany. Melanoma-specific survival curves and estimated survival probabilities were generated using the Kaplan-Meier method. Multivariate survival analyses were carried out using the Cox modeling. Male patients had significantly thicker and more frequently ulcerated tumors and a lower 10-year disease-specific survival (DSS) and recurrence-free survival probability compared with females among patients of 43 years old or younger (DSS: 86.1 vs. 93.2%, P<0.001) and 44-60 years old (DSS: 83.5 vs. 90.1%, P<0.001). The survival advantage of female patients in terms of 10-year DSS and 10-year recurrence-free survival was not observed after an age of 60 years (P=0.21 and 0.51, respectively). Sex was of prognostic importance for DSS and survival after recurrence [hazards ratio (HR): 1.3; 95% confidence interval (CI): 1.1-1.6; P=0.002 and HR: 1.2; 95% CI: 1.0-1.5; P=0.018, respectively]. Stratified by age groups, sex remained of prognostic importance for DSS only in patients of 43 years or younger, and 44-60 years old (HR: 1.5; 95% CI: 1.0-2.1; P=0.03 and HR: 1.4; 95% CI: 1.1-2.0; P=0.02, respectively). Sex is an independent prognostic factor in surviving melanoma. The sex difference in survival with a better outcome for women is confined to melanoma patients of 60 years and younger. In addition, in younger age groups, male patients present with prognostically unfavorable features of primary melanoma. A female survival advantage is also known for other solid tumors such as colon and lung cancer; however, age dependency has not been studied.

show abstract

Section: Introductionmentioning

confidence: 99%

“…A significant increase in the incidence of melanoma has been observed in the last few decades prompting an improvement in diagnostic ability and early treatment with an important increase in the survival index. 1 The improved management of the disease, however, has not resulted in better control of neoplastic spread to regional lymph nodes for lesions thicker than 0.76 mm. In these cases, occult metastatic spread occurs in variable percentages between 8 and 27% of cases 2 with a substantial reduction in the 10-year survival rates for patients with one, two to four, or more than four positive nodes, at 40%, 26% and 15%, respectively.…”

Section: Introductionmentioning

confidence: 99%

Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases

Landi¹,

Polverelli²,

Moscatelli

et al. 2000

Acad Dermatol Venereol

View full text Add to dashboard Cite

Our data confirm in a large series of cases that the SLN biopsy is extremely selective and useful to find early micrometastases and to identify patients needing regional lymphadenectomy and adjuvant immunotherapy. Patients with intermediate thickness melanoma (0.76-4.0 mm) should be informed on the availability of such a revolutionary procedure, which represents a new opportunity in primary melanoma surgery.

show abstract

Gender, geography and socio-economic status in the diffusion of malignant melanoma risk

Cited by 29 publications

References 29 publications

Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia

Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia

Sex differences in survival of cutaneous melanoma are age dependent

Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases

Contact Info

Product

Resources

About